Page last updated: 2024-11-12
ap 1903 reagent
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
AP 1903 reagent: a dimerizer drug [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 16135625 |
| CHEMBL ID | 269259 |
| SCHEMBL ID | 10111062 |
| MeSH ID | M0384358 |
Synonyms (37)
| Synonym |
|---|
| ap1903 |
| rimiducid , |
| CHEMBL269259 |
| ap-1903 |
| S9726 |
| 2-piperidinecarboxylic acid, 1-(1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene(3-(3,4-dimethoxyphenyl)propylidene)) ester, (2s-(1(r*),2r*(s*(s*(1(r*),2r*)))))- |
| h564l1w5j2 , |
| unii-h564l1w5j2 |
| ap 1903 |
| rimiducid [inn] |
| rimiducid [usan:inn] |
| ap 1903 reagent |
| 195514-63-7 |
| 2-piperidinecarboxylic acid, 1-((2s)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl)-, 2,2'-(1,2-ethanediylbis(imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene((1r)-3-(3,4-dimethoxyphenyl)propylidene))) ester, (2s,2's)- |
| CS-3162 |
| HY-16046 |
| rimiducid [usan] |
| rimiducid [who-dd] |
| SCHEMBL10111062 |
| DTXSID80173226 |
| AKOS030238859 |
| DB04974 |
| EX-A1711 |
| (1r,1'r)-((((ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl) (2s,2's)-bis(1-((s)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate) |
| D11195 |
| rimiducid (usan/inn) |
| Q27279658 |
| A919658 |
| AT37167 |
| MS-32155 |
| [(1r)-3-(3,4-dimethoxyphenyl)-1-[3-[2-[2-[[2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-[(2s)-2-(3,4,5-trimethoxyphenyl)butanoyl]piperidine-2-carbonyl]oxypropyl]phenoxy]acetyl]amino]ethylamino]-2-oxoethoxy]phenyl]propyl] (2s)-1-[(2s)-2-(3,4,5-trimethoxyph |
| rimiducid (ap1903) |
| ap1903ap1903 |
| VHA51463 |
| ap 1903new |
| (1r,1'r)-((((ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl)(2s,2's)-bis(1-((s)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate) |
| AC-35487 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cellular therapies could play a role in cancer treatment and regenerative medicine if it were possible to quickly eliminate the infused cells in case of adverse events." | ( Inducible apoptosis as a safety switch for adoptive cell therapy. Brenner, MK; Cruz, CR; Di Stasi, A; Dotti, G; Durett, AG; Fujita, Y; Gee, AP; Grilley, B; Heslop, HE; Kennedy-Nasser, A; Krance, RA; Liu, E; Liu, H; Martinez, C; Rooney, CM; Savoldo, B; Schindler, J; Spencer, DM; Straathof, K; Tey, SK, 2011) | 0.37 |
| " However, after CID treatment, 1% of iC9-T cells remain and can regrow over time; although these resurgent T cells do not cause recurrent GvHD, it remains unclear whether repeat CID treatments are a safe and feasible way to further deplete residual gene-modified T cells should any other adverse effects associated with them occur." | ( Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Brenner, MK; Dakhova, O; Dotti, G; Heslop, HE; Naik, S; Zhou, X, 2016) | 0.43 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Twenty-eight normal healthy male volunteers were randomized into five dosage groups of AP1903 (0." | ( Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. Berger, HJ; Clackson, T; Dalgarno, D; Iuliucci, JD; Morley, S; Oliver, SD; Ward, C; Ward, J, 2001) | 0.31 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (5)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID84259 | Compound was induced transcription stably transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19 | Regulation of gene expression by synthetic dimerizers with novel specificity. |
| AID84263 | Compound was induced transcription stably transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19 | Regulation of gene expression by synthetic dimerizers with novel specificity. |
| AID84260 | Compound was induced transcription stably transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells; No induction | 2003 | Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19 | Regulation of gene expression by synthetic dimerizers with novel specificity. |
| AID84262 | Compound was induced transcription in transiently transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19 | Regulation of gene expression by synthetic dimerizers with novel specificity. |
| AID84130 | Compound was induced transcription in transiently transfected with constructs encoding separate DNA-binding domain and activation domain proteins in HT1080 human fibrosarcoma cells | 2003 | Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19 | Regulation of gene expression by synthetic dimerizers with novel specificity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 11 (64.71) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.60
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.60) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (23.53%) | 5.53% |
| Reviews | 1 (5.88%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (70.59%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||